These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

2764 related items for PubMed ID: 23291072

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Paclitaxel and carboplatin as neoadjuvant chemotherapy in patients with locally advanced breast cancer: A phase II Trial of the Hellenic Cooperative Oncology Group.
    Gogas H, Pectasides D, Kostopoulos I, Lianos E, Skarlos D, Papaxoinis G, Bobos M, Kalofonos HP, Petraki K, Pavlakis K, Bafaloukos D, Fountzilas G.
    Clin Breast Cancer; 2010 Jun; 10(3):230-7. PubMed ID: 20497922
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Phase II study of neoadjuvant weekly nab-paclitaxel and carboplatin, with bevacizumab and trastuzumab, as treatment for women with locally advanced HER2+ breast cancer.
    Yardley DA, Raefsky E, Castillo R, Lahiry A, Locicero R, Thompson D, Shastry M, Burris HA, Hainsworth JD.
    Clin Breast Cancer; 2011 Oct; 11(5):297-305. PubMed ID: 21729666
    [Abstract] [Full Text] [Related]

  • 8. [Efficacy analysis of THP-containing regimens as neoadjuvant and adjuvant chemotherapy for primary breast cancer].
    Wang LZ, Ouyang T, Wang TF, Xie YT, Fan ZQ, Fan T, Lin BY, Li JF.
    Zhonghua Zhong Liu Za Zhi; 2012 Feb; 34(2):143-6. PubMed ID: 22780935
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of changes of biologic markers ER, PR, HER 2 and Ki-67 in breast cancer with administration of neoadjuvant dose-dense doxorubicin, cyclophosphamide followed by paclitaxel.
    Dede DS, Gumuskaya B, Guler G, Onat D, Altundag K, Ozisik Y.
    J BUON; 2013 Feb; 18(1):57-63. PubMed ID: 23613389
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Weekly paclitaxel plus carboplatin is an effective nonanthracycline-containing regimen as neoadjuvant chemotherapy for breast cancer.
    Chen XS, Nie XQ, Chen CM, Wu JY, Wu J, Lu JS, Shao ZM, Shen ZZ, Shen KW.
    Ann Oncol; 2010 May; 21(5):961-7. PubMed ID: 20211870
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Preoperative carboplatin-paclitaxel-bevacizumab in triple-negative breast cancer: final results of the phase II Ca.Pa.Be study.
    Guarneri V, Dieci MV, Bisagni G, Boni C, Cagossi K, Puglisi F, Pecchi A, Piacentini F, Conte P.
    Ann Surg Oncol; 2015 Sep; 22(9):2881-7. PubMed ID: 25572687
    [Abstract] [Full Text] [Related]

  • 20. Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial.
    Loibl S, O'Shaughnessy J, Untch M, Sikov WM, Rugo HS, McKee MD, Huober J, Golshan M, von Minckwitz G, Maag D, Sullivan D, Wolmark N, McIntyre K, Ponce Lorenzo JJ, Metzger Filho O, Rastogi P, Symmans WF, Liu X, Geyer CE.
    Lancet Oncol; 2018 Apr; 19(4):497-509. PubMed ID: 29501363
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 139.